CAMBRIDGE, Mass., March 28,
2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc.
(NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients through
the discovery, development and commercialization of transformative
targeted therapies, today announced that the company will
participate in the Cantor Future of Oncology Virtual Symposium,
taking place April 3-5, 2023.
Event: Cantor Future of Oncology Virtual Symposium
Panel Date / Time: Monday, April
3rd at 2:00pm
ET
A live webcast will be available for registered attendees and
clients of Cantor.
About Theseus Pharmaceuticals, Inc.
Theseus is a
clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients through the discovery, development, and
commercialization of transformative targeted therapies. Theseus is
working to outsmart cancer resistance by developing pan-variant
tyrosine kinase inhibitors (TKIs) to target all classes of
cancer-causing and resistance mutations that lead to clinically
relevant variants in a particular protein in a given type of
cancer. Theseus' lead product candidate, THE-630, is a pan-variant
KIT inhibitor for the treatment of patients with advanced
gastrointestinal stromal tumors (GIST), whose cancer has developed
resistance to earlier lines of kinase inhibitor therapy. Theseus is
also developing THE-349, a fourth-generation, selective epidermal
growth factor receptor (EGFR) inhibitor for C797X-mediated
resistance to first- or later-line osimertinib treatment in
patients with non-small cell lung cancer (NSCLC), and a pan-variant
BCR-ABL inhibitor for the treatment of relapsed/refractory chronic
myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute
lymphoblastic leukemia (ALL). For more information, visit
www.theseusrx.com.
Media Contact
Christen
Baglaneas
Director, Corporate Communications & Investor Relations
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Investor Contact
Josh
Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-the-cantor-future-of-oncology-virtual-symposium-301782407.html
SOURCE Theseus Pharmaceuticals
